
Reata Pharmaceuticals RETA
Quarterly report 2023-Q1
added 05-10-2023
Reata Pharmaceuticals DPO Ratio 2011-2026 | RETA
Annual DPO Ratio Reata Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 5.6 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.6 | 5.6 | 5.6 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Verastem
VSTM
|
1.26 K | $ 5.04 | -4.73 % | $ 349 M | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
35.1 | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
Xenon Pharmaceuticals
XENE
|
40.5 | $ 54.48 | -1.89 % | $ 4.24 B | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
Summit Therapeutics
SMMT
|
84.9 K | $ 16.58 | -3.94 % | $ 12.4 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
55 | $ 317.36 | -3.29 % | $ 41.6 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.29 | -3.6 % | $ 822 M | ||
|
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 19.01 | -2.66 % | $ 889 M | ||
|
Завод ДИОД
DIOD
|
30.3 | - | - | - | ||
|
Фармсинтез
LIFE
|
306 | - | - | - | ||
|
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 20.75 | -3.35 % | $ 3.44 B | ||
|
Teligent, Inc.
TLGT
|
59.2 | - | -13.85 % | $ 16.1 M | ||
|
Viela Bio, Inc.
VIE
|
997 | - | - | $ 2.91 B | ||
|
Alkermes plc
ALKS
|
143 | $ 29.39 | -1.77 % | $ 4.84 B | ||
|
AbbVie
ABBV
|
65.5 | $ 209.4 | -0.81 % | $ 370 B | ||
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |